Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-12-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于2020年股票期权激励计划股票期权授予登记完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the registration of stock options granted under the company's 2020 stock option incentive plan. It details the approval process, the number of options granted, the recipients, exercise conditions, and the expected accounting impact. It is a formal disclosure about a stock option grant event, including legal opinions and board approvals, but it does not contain financial statements or quarterly/yearly financial results. It is not an annual or interim report, earnings release, or management discussion. The content fits best under Capital/Financing Update (CAP) because it relates to the company's equity incentive plan and issuance of stock options, which affects capital structure and financing activities. The document length is sufficient and contains detailed information about the stock option grant, not just a brief announcement or a certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2020-12-04 Chinese
独立董事关于第四届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to a board meeting, specifically regarding the stock option incentive plan granted on November 24, 2020. It references compliance with regulatory guidelines and company governance but does not contain financial statements or detailed financial results. The document is focused on board-level decisions and governance matters related to stock option grants, which aligns with Board/Management Information filings rather than full financial reports or announcements of voting results. The document length is short and it is not an announcement of a report publication or a certification letter. Therefore, the most appropriate classification is Board/Management Information (MANG).
2020-11-24 Chinese
第四届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the approval of a stock option incentive plan. It includes details about the meeting date, participants, agenda, and voting results. The content focuses on governance and internal approval processes rather than financial results or detailed financial data. It does not contain financial statements or comprehensive financial analysis. The document is an official announcement of a board/management decision related to stock option grants, which fits the category of Board/Management Information (MANG). The document length is short (1205 characters), and it is not a report or a presentation but a formal meeting resolution announcement.
2020-11-24 Chinese
第四届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Yunnan Watson Biotechnology Co., Ltd. It details the convening of the fourth board's fifteenth meeting, the approval of a stock option incentive plan, voting results, and mentions related legal opinions and independent director opinions. The document is short (1087 characters) and primarily serves to announce the board's decision rather than provide detailed financial data or a full report. It does not contain financial statements or comprehensive management discussion. Therefore, it fits best as a Board/Management Information (MANG) filing, which covers announcements of board decisions and management matters.
2020-11-24 Chinese
北京国枫律师事务所关于公司2020年股票期权激励计划授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2020 stock option incentive plan grant for Yunnan Watson Biotechnology Co., Ltd. It details the approval, authorization, and compliance with relevant laws and regulations for the stock option plan. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital incentive plan. It does not announce a report publication but provides a detailed legal opinion on a specific corporate action. This fits best under Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and stock option plans, not a direct financial or management report or announcement of voting results or capital changes.
2020-11-24 Chinese
监事会关于2020年股票期权激励计划股票期权授予日激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board regarding the verification of the list of incentive recipients for a 2020 stock option incentive plan. It references legal compliance and approval of the stock option grant but does not contain financial statements or detailed financial performance data. The document length is short (1066 characters) and it is an official statement about the stock option incentive plan and its recipients, not a full report or financial filing. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about stock option incentives and compliance, not a full capital/financing update or annual report.
2020-11-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.